Prevention and Control of Selected Non-Communicable Diseases in Sri Lanka:
Policy Options and Action
Health, Nutrition and Population Discussion Paper

This series is produced by the Health, Nutrition, and Population Family (HNP) of the World Bank’s Human Development Network. The papers in this series aim to provide a vehicle for publishing preliminary and unpolished results on HNP topics to encourage discussion and debate. The findings, interpretations, and conclusions expressed in this paper are entirely those of the author(s) and should not be attributed in any manner to the World Bank, to its affiliated organizations or to members of its Board of Executive Directors or the countries they represent. Citation and the use of material presented in this series should take into account this provisional character. For free copies of papers in this series please contact the individual author(s) whose name appears on the paper.

This publication is a summary of the main report on 'Prevention and Control of Selected Chronic NCDs in Sri Lanka: Policy Options and Action; published as a Health, Nutrition and population Discussion Paper of the World Bank in October 2010.

Concept & Photographs - Anoma Rajakaruna, Design - NEO Graphics
Prevention and Control of Selected Non-Communicable Diseases in Sri Lanka:
Policy Options and Action

October 2010

THE WORLD BANK
Introduction

Sri Lanka, now a middle income country, is already at the advanced stages of aging and disease transitions. This is evident from the fact that the life expectancy of the population has increased along with an increase of the Non Communicable Diseases burden over the last decades. Strategic approaches adopted to improve the quality of health services for Non communicable disease affected persons will enable healthier aging and reduce loss of productivity among the working age group population in Sri Lanka. This report aims to stimulate policy dialogue for control and prevention of NCDs and to provide an evidence base for selected Non Communicable diseases to facilitate decisions required to improve the quality of NCD services to the people of Sri Lanka. While the definition of NCDs include a group of diseases related to cardiovascular disease, diabetes mellitus, cancer, asthma and other chronic obstructive pulmonary diseases, mental health and injuries and violence; this report has selected heart diseases, diabetes mellitus, asthma and some information on cancer for this analysis.
Non-communicable Diseases (NCDs)
The Emerging Disease Burden
Population aging is well under way

The Population aging (demographic transition) is now well under way with life expectancy at 74 years and the proportion of people 60 years and older is expected to double from 12.1% in 2010 to 24.4% in 2040.

Proportion of people in older (> 60 years) age groups, Sri Lanka 2001–2100

Life expectancy gains for men are far less than for women. Females have made steady gains since 1920 while gains among males have stalled since 1980.

Changes in life expectancy at 30 years of age, Sri Lanka and the United States, 1921-2001

Source: Sri Lanka from Sarkar (1951), Department of Census and Statistics (1970); De Silva (2007); and Institute for Health Policy's computations from the same sources; the United States from Bell and Miller (2005)
A shift in disease burden is also under way

NCDs now account for approximately 85% of the disease burden epidemiologic transition. The disease burden is shifting from maternal and child health and Infectious diseases towards NCDs (acute and chronic NCDs).

Disease burden in selected regions and countries, 2004

- During the past half century the proportion of deaths due to circulatory disease (for example, heart disease, stroke) increased from 3% to 24% while that due to infectious diseases decreased from 24% to 12%. Diabetes and cancer are also increasing.
The NCD burden increases the need for long-term care. This care is especially needed for the elderly as they suffer more from NCDs. Similarly, NCDs also affect labor-force participation especially by older working-age adults. Both these effects have a significant impact, the former through higher costs of health care and the latter through productivity losses.
NCD burden is shifting to the poor
In developed countries, NCDs disproportionately affect the poor. Current evidence suggests that in Sri Lanka the rich suffer more from some NCDs than the poor, but this pattern is changing and shifting towards the poor.

In Sri Lanka, heart disease deaths have tended to be higher among the rich while asthma deaths are highest among the poorer population groups. These high asthma death rates may, in part, be due to poor access to treatment.

Mortality from IHD and asthma by SES quintiles, Sri Lanka, 1999–2003

Source: Data provided from analysis by Chamara et al., November 2009, Institute for Health policy. Mortality data for Sri Lanka from IHP Register General Analysis Project. Analysis by Institute for Health Policy Equitap Mortality Differentiation Project.
Prevalence of major NCD risk factors is expected to increase

- Obesity, which is more common in women and in urban areas and has been increasing for the past 20 years, increases the risk of heart disease.

- Tobacco use is almost exclusively found among men (32% for men and 2% for women) and is higher among the poor. Tobacco use increases the risk of heart disease, chronic respiratory illness and lung cancer.
Health services for NCDs
Health services for NCDs are mostly delivered at higher-level public facilities, and need significant improvements

- The public sector provides 50% of outpatient care and 90% of inpatient care.
- Bed occupancy rates are 56–83% in higher-level facilities and 47% in lower-level facilities.
- Approximately 66% of clinic-based services (mainly for chronic NCDs) are provided through higher level facilities, though most of it could be handled at lower level facilities at less cost, if the latter could be equipped for it.
- Primary health care facilities are not managing the complete spectrum of chronic NCDs.
- Essential clinical investigation and medical equipment necessary to diagnose and manage NCDs are often not available at primary and secondary care levels.

Consumption of Beta blockers (as an NCD medicine) in defined daily dose units (DDD), Sri Lanka and OECD countries

- Low availability of essential NCD medications is a problem at all levels but most severe at lower levels. The short supply of key medication and its impact is confirmed by the overall rates of essential NCD medicine use in Sri Lanka being at the lower end of the range among countries with comparable NCD burden patterns. One explanation for this is the low volume of essential NCD medicines available in the public sector. An example can be seen in the graph below, comparing Sri Lanka's consumption of Beta blockers (drugs used in heart disease) with that of other developed countries (instead of OECD).
Health spending in Sri Lanka is low

- Total health expenditures increased from 3.5% of GDP in 1995 to 4.0% in 2008, of which the share of public spending declined from 47% to 43%. These overall expenditures are less than expected for the country's level of national income.

NCD care is increasingly financed by out-of-pocket spending

- The expenditures for treatment of cancers and acute heart attacks in 2005 were predominantly publicly financed (92 percent and 57 percent from public sources, respectively) while those for diabetes, asthma, and heart disease were predominantly privately financed (19 percent, 13 percent, and 26 percent from public sources, respectively). Private expenditures are mainly out of pocket.

- For cardiovascular disease, diabetes, and asthma, about half the out-of-pocket expenditures are for outpatient care and drugs.

Expenditures on major NCDs, by public and private sources (%), Sri Lanka 2005

<table>
<thead>
<tr>
<th>Disease</th>
<th>Public</th>
<th>Private</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malignant neoplasms</td>
<td>91.9</td>
<td>8.1</td>
</tr>
<tr>
<td>Other ischemic heart disease</td>
<td>26.3</td>
<td>73.7</td>
</tr>
<tr>
<td>Acute myocardial infarction</td>
<td>56.9</td>
<td>43.1</td>
</tr>
<tr>
<td>Diabetes Mellitus</td>
<td>18.8</td>
<td>81.2</td>
</tr>
<tr>
<td>Asthma</td>
<td>13.4</td>
<td>86.6</td>
</tr>
</tbody>
</table>

The Tools to Respond
NCDs Prevention and
Control strategies
**NCD interventions are cost effective**

- There are cost-effective population-level and clinic-level interventions to prevent and treat NCDs. Population-level interventions might be aimed at changing dietary behaviors.

### Selected population-based interventions

<table>
<thead>
<tr>
<th>Condition</th>
<th>Intervention</th>
<th>Intervention description</th>
<th>Target population</th>
<th>Cost-effectiveness (US$/DALY)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coronary artery disease</td>
<td>Legislation</td>
<td>Legislation replacing 2% of dietary trans fat from partial hydrogenation in manufactured foods with polyunsaturated fat, at a cost of US$0.50 per adult, and assuming a 7% reduction in coronary artery disease.</td>
<td>Adults</td>
<td>48</td>
</tr>
<tr>
<td>Diabetes, ischemic heart disease, and stroke</td>
<td>Legislation</td>
<td>Legislated reduction in salt content of manufactured foods and an accompanying public education campaign.</td>
<td>All ages</td>
<td>1,937</td>
</tr>
<tr>
<td>Tobacco addiction (CVD, chronic respiratory disease, cancer)</td>
<td>Taxation</td>
<td>A 33% price increase due to tobacco taxes to discourage tobacco use, prevent initiation (and subsequent addiction) among youths, increase the likelihood of cessation among current users, reduce relapse among former users and reduce consumption among continuing users.</td>
<td>Adolescents and adults</td>
<td>22</td>
</tr>
</tbody>
</table>


Clinic-based actions focusing on individuals could include the control of diabetes, cholesterol, high blood pressure, and screening for cancer.

### Selected clinic-based interventions

<table>
<thead>
<tr>
<th>Condition</th>
<th>Intervention</th>
<th>Target population</th>
<th>Cost-effectiveness (US$/DALY)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischemic heart disease</td>
<td>Aspirin, beta blocker</td>
<td>Adults</td>
<td>688</td>
</tr>
<tr>
<td>Heart attack</td>
<td>Aspirin, beta blocker</td>
<td>Adults</td>
<td>14</td>
</tr>
<tr>
<td>Heart attack and stroke</td>
<td>Polypill*</td>
<td>Adults</td>
<td>409</td>
</tr>
<tr>
<td>Stroke</td>
<td>Aspirin</td>
<td>Adults</td>
<td>149</td>
</tr>
<tr>
<td>Diabetes</td>
<td>Foot care in people with high risk users</td>
<td>Adults</td>
<td>Cost saving</td>
</tr>
<tr>
<td>Cervical cancer</td>
<td>Cervical cytology screening</td>
<td>Adults</td>
<td>39-81</td>
</tr>
</tbody>
</table>


Note: Combination treatment with aspirin, beta-blocker, thiazide diuretics, ACE inhibitor and statin, based on 10-year risk of cardiovascular disease.
Population and clinic level interventions can significantly reduce deaths caused by heart disease.

- Population-based risk factor reduction and clinic-based interventions (with drugs) can substantially reduce mortality, by up to 23 percent (38,000 deaths) of that otherwise expected.

Deaths avoided at 10 years under different intervention strategies for heart disease among Sri Lankans, 18–74 years

<table>
<thead>
<tr>
<th>Intervention strategy</th>
<th>Number of avoided deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>High baseline risk with two interventions</td>
<td>37,660</td>
</tr>
<tr>
<td>Population strategy (9% Cholesterol reduction)</td>
<td>25,160</td>
</tr>
<tr>
<td>High baseline risk with statins</td>
<td>24,309</td>
</tr>
<tr>
<td>High baseline risk with antihypertensives</td>
<td>16,909</td>
</tr>
<tr>
<td>Population strategy (2% Cholesterol reduction)</td>
<td>5,073</td>
</tr>
<tr>
<td>Single risk factor strategy</td>
<td>1,747</td>
</tr>
</tbody>
</table>

Source: Institute for Health Policy computations using Framingham cardiovascular risk prediction equation and data from Katulanda et al., 2008.
Policy Options for Effective NCD Response
Program

- Focus on selected diseases such as cardio-vascular disease (CVD), diabetes, asthma, and cancer, in view of their disease burden and availability of cost-effective interventions.
- Create an intensified national NCD control program for developing, organizing, and implementing national prevention and control policy with sufficient resources and authority to make it effective, working through existing systems and structures.
- Create a national NCD surveillance system suitable for strategic planning and policy development.

Health Services

- Increase use of lower-level public health facilities for NCD care, by ensuring the availability of acceptable quality of care, especially in terms of NCD drugs and clinical investigation capacity.
- Coordinate preventive and curative care services and align them to provide the spectrum of services required to mount an appropriate response to NCDs.
- Increased access to NCD drugs, especially for the poor by increasing the drug supply through public financing and/or procurement.
- Decentralize health services with the aim to better coordinate care among different facility levels and allow the central ministry to focus on policy, governance, and regulation.
Financing

- Develop health financing strategies that mobilize greater resources for NCD prevention and control (from both public and private sources), mitigate the potentially impoverishing effects of out-of-pocket health expenditures, establish mechanisms for higher contributions to health services from richer population groups, increase efficiencies in the public sector, and raise public financing of NCD drugs targeted to the poorer segments of the population.

Human Resources

- Develop a well-trained and competent health work focus to tackle NCDs in adequate numbers and appropriate categories, who are capable of treating, counseling, screening, and providing other preventive NCD services.

Public-Private Partnerships

- Engage the private sector in both financing and provision of NCD care. This could take the form of contracting, franchising, regulating, sharing information, etc. The first step would be to conduct a Private Health Sector Assessment, since it remains poorly understood and its outputs mostly uncharacterized, yet it makes a substantial contribution to service provision for NCDs.
Acknowledgments

This report was prepared by the core team of Michael Engelgau (task team leader), Kyoko Okamoto, Kumari Vinodhani Navaratne, and Sundararajan Gopalan.

Several others made major contributions through source documents used in formulating the report. Source documents for Chapters 2–6 was written by Ravi P. Rannan-Eliya, Chamara Anuranga, Lara Brearley, Ruwanthi Elwalagedara, A.P.T.L. Abeykoon, Ahalya Balasundaram, and Shanti Dalpatadu (Institute for Health Policy, Sri Lanka) and for Chapter 3 by Shanti Dalpatadu, Ruwanthi Elwalagedara, and Achana Obris (also of the Institute for Health Policy, Sri Lanka). Contributions to the executive summary were made by Naoko Ohno and to Chapter 7 by Tekabe Belay, both of the World Bank.

Very helpful comments on various drafts were given by Tania Dmytraczenko, Kees Kostermans, Charu Garg, Tekabe Belay, Nkosinathi Mbaya, and Angela DeSilva, all of the World Bank.

During three workshops with the Government of Sri Lanka and the Ministry of Health (MOH) very useful comments were provided and we want thank the following for their contributions: Dr. Terrence De Silva (DDG Medical Services), Dr. R.R.M.L.R. Siyabalagoda (DDG PHS 11), Dr. P. Maheepala (DDG PHS 1), Dr. L. Pannapitiya (Director NCD), Dr. Susie Perera (Director Policy Analysis), Dr. A. Dissanayake (Director YEDD), Dr. N. Kanakan (Consultant Community Physician, Epidemiology Unit), Dr. Palitha Karunapema (CCP, NCD Unit), Dr. Vindya Kumarapeli (CCP, NCD Unit), and Dr. Amala De Silva (Health Economist, University of Colombo). We also want to acknowledge the help of MOH staff Ms. Susantha Ranadheera (Head, Vital Statistics Unit, Registrar General’s Department), Mr. Migara Fernando, Consultant, VS Unit, RG Department, Ms. Indu Bandara, Medical Statistics Unit, MOH, Mrs. Krishnathi Jayawardena, Medical Statistics Unit, MOH, and Mr. E.M.M.K. Ekanayake, Medical Statistics Unit, MOH for their support and assistance during data collection. We also want to acknowledge all support for this work from the former Secretary, MOH, Dr. H.A.P. Kahandhaliyanage.

The core team is very grateful to the peer reviewers for the report, who included Peter Berman, Montserrat Meiro-Lorenzo, and Akiko Maeda from the World Bank, Shanthi Mendis from the World Health Organization, Geneva, and Saroj Jayasinghe from the University of Colombo.

Finally we want to acknowledge the operational support provided by Silvia Albert, Eldreda Vincent, Gertrude Cooper, Alejandro Welch, and Kerima Thilakasena, all of the World Bank, and the assistance in editing the report provided by Jonathan Aspin (consultant).